BridgeMD
New treatment option for Stem Cell Transplantation
Official title A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
ClinicalTrials.gov ID: NCT06743477
What this study is testing
- What it's testing
- Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 7 to 12
You may be able to join if
- Patient
- Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types;
- Age between 7-12 years old, male or female not limited; Weight\<40kg
- The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell...
- There are HLA matched or mismatched donors who meet the donor criteria through physical examination;
You likely can't join if
- for patients:
- Psychiatric patients;
- Participants in clinical trials of other drugs within the past month;
- There are no suitable HLA mismatched donors available.
- Other researchers have determined that they are not suitable to participate in this study. （3） Supplier screening criteria:
- HLA typing matches the patient's haplotype
See the full eligibility criteria
- Patient
- Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types;
- Age between 7-12 years old, male or female not limited; Weight\<40kg
- The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell transplantation treatment; And patients who unconditionally or refuse to undergo...
- There are HLA matched or mismatched donors who meet the donor criteria through physical examination;
- The patient and their family agree to receive super transplantation treatment and sign a written informed consent form before the transplantation trial. （2）
- for patients:
- Psychiatric patients;
- Participants in clinical trials of other drugs within the past month;
- There are no suitable HLA mismatched donors available.
- Other researchers have determined that they are not suitable to participate in this study. （3） Supplier screening criteria:
- HLA typing matches the patient's haplotype
- KIR configuration
- NIMA
- DSA negative
- Routine physical examination
- Genetic screening for carriers of thalassemia, mild or no carriers of thalassemia
- Sign the informed consent form.
The study team makes the final eligibility decision.
Where it's taking place
- Kunming, Yunnan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 7 years to 12 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kunming, Yunnan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.